for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Biogen Inc

BIIB.OQ

Latest Trade

238.79USD

Change

0.00(0.00%)

Volume

20

Today's Range

--

 - 

--

52 Week Range

215.81

 - 

358.35

As of on the NASDAQ ∙ Minimum 15 minute delay

Pricing

Previous Close
238.79
Open
0.00
Volume
20
3M AVG Volume
30.18
Today's High
--
Today's Low
--
52 Week High
358.35
52 Week Low
215.81
Shares Out (MIL)
184.45
Market Cap (MIL)
44,044.15
Forward P/E
7.42
Dividend (Yield %)
--

Next Event

Q3 2019 Biogen Inc Earnings Call

Latest Developments

More

Biogen Advances Spinal Muscular Atrophy Clinical Research

Samsung Bioepis Announced Expansion Into Brazilian Biopharmaceutical Market

Biogen Says Diroximel Fumarate Demonstrated Improved Gastrointestinal Tolerability Profile Compared To Dimethyl Fumarate In Patients With Multiple Sclerosis

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Biogen Inc

Biogen Inc. is a biopharmaceutical company. The Company focuses on discovering, developing, manufacturing and delivering therapies to people living with serious neurological, rare and autoimmune diseases. The Company markets products, including TECFIDERA, AVONEX, PLEGRIDY, TYSABRI, ZINBRYTA and FAMPYRA for multiple sclerosis (MS), FUMADERM for the treatment of severe plaque psoriasis and SPINRAZA for the treatment of spinal muscular atrophy (SMA). It also has a collaboration agreement with Genentech, Inc. (Genentech), a member of the Roche Group, with respect to RITUXAN for the treatment of non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL) and other conditions, GAZYVA indicated for the treatment of CLL and follicular lymphoma, and other anti-CD20 therapies. The Company's product candidate includes OCREVUS; Biosimilar adalimumab; Aducanumab; E2609; BIIB074; BAN2401; Opicinumab; CIRARA; BIIB061; BIIB054; BIIB067, and BIIB068.

Industry

Biotechnology & Drugs

Contact Info

225 Binney St

+1.781.4642000

https://www.biogen.com/

Executive Leadership

Stelios B. Papadopoulos

Independent Chairman of the Board

Michel Vounatsos

Chief Executive Officer, Director

Jeffrey D. Capello

Chief Financial Officer, Executive Vice President

Ginger Gregory

Chief Human Resource Officer, Executive Vice President

Susan H. Alexander

Executive Vice President, Chief Legal Officer and Secretary

Key Stats

2.86 mean rating - 29 analysts
Sell
Hold
Buy
Revenue (MM, USD)

2016

11.4K

2017

12.3K

2018

13.5K

2019(E)

14.2K
EPS (USD)

2016

20.220

2017

21.810

2018

26.200

2019(E)

32.195
Price To Earnings (TTM)
8.84
Price To Sales (TTM)
3.13
Price To Book (MRQ)
3.41
Price To Cash Flow (TTM)
6.99
Total Debt To Equity (MRQ)
45.92
LT Debt To Equity (MRQ)
45.92
Return on Investment (TTM)
24.42
Return on Equity (TTM)
21.33

Latest News

Biogen scraps two late-stage trials for Alzheimer's treatment

Biogen Inc and Eisai Co Ltd are abandoning two late-stage trials for their Alzheimer's treatment in a widely anticipated move that comes months after the companies scrapped trials of another drug for the memory-robbing disease.

Biogen scraps two late-stage Alzheimer's trials

Biogen Inc and partner Eisai Co Ltd said on Friday they would abandon two late-stage trials testing their experimental treatment, elenbecestat, for patients with early Alzheimer's disease.

Multiple sclerosis drug helps Biogen beat Wall St. profit expectations

Biogen Inc reported better-than-expected second quarter profit and raised its 2019 earnings forecast on Tuesday, driven by higher sales of its top-selling multiple sclerosis drug Tecfidera and lower taxes.

Biogen profit rises 72%

Drugmaker Biogen Inc reported a 72.4% rise in second-quarter profit on Tuesday, boosted by higher sales of its multiple sclerosis treatment Tecfidera and lower research and development costs.

NHS England, Biogen reach deal on pricey drug for deadly disorder

England's National Health Service said it had reached a deal to pay for U.S. drugmaker Biogen Inc's expensive spinal muscle atrophy treatment Spinraza.

NHS England, Biogen reach deal on pricey drug for deadly disorder

England's National Health Service said it had reached a deal to pay for U.S. drugmaker Biogen Inc's expensive spinal muscle atrophy treatment Spinraza.

AbbVie says Humira rivals from Biogen, Amgen most aggressive so far

AbbVie Inc's Chief Executive Officer Richard Gonzalez said on a conference call that rivals Biogen Inc and Amgen Inc had been the most aggressive in Europe with their biosimilar versions of its blockbuster drug Humira.

AbbVie says Humira rivals from Biogen, Amgen most aggressive so far

AbbVie Inc's Chief Executive Officer Richard Gonzalez said on a conference call that rivals Biogen Inc and Amgen Inc had been the most aggressive in Europe with their biosimilar versions of its blockbuster drug Humira.

Biogen dips as strategy post Alzheimer's setback fails to impress

Biogen Inc on Wednesday beat Wall Street estimates for quarterly profit, but failed to ease investor concerns about long-term growth after it recently shelved the development of an Alzheimer's drug that was expected to be its next blockbuster, sending its shares down 2 percent...

Biogen first-quarter profit rises 20 percent

Drugmaker Biogen Inc reported a 20 percent rise in first-quarter profit on Wednesday on higher sales of its muscle disease treatment Spinraza.

Biogen SMA drug price, Novartis estimates for its treatment far too high - U.S. group

Biogen Inc should slash the price of its spinal muscular atrophy (SMA) drug, and the $4 million to $5 million Novartis has said its experimental gene therapy for the disease is worth is excessive, an independent U.S. organization that reviews the value of medical treatments...

Biogen announces $5 billion buyback days after shelving Alzheimer's trials

Biogen Inc said on Monday it would buy back shares worth $5 billion, days after its stock slumped on the drugmaker's announcement to end two Alzheimer's disease trials.

Eisai starts phase 3 trials for second Alzheimer's drug after first's failure

Eisai Co Ltd on Friday said it has begun phase 3 clinical trials of Alzheimer's treatment BAN2401, a day after the Japanese drugmaker and U.S. partner Biogen Inc scrapped trials for another Alzheimer's drug, aducanumab.

Biogen scraps two Alzheimer drug trials, wipes $18 billion from market value

Biogen Inc and partner Eisai Co Ltd are ending two late-stage trials of their experimental Alzheimer's disease drug aducanumab, a major setback in the quest to find a treatment for the mind-wasting disease and a blow to Biogen, which lost more than $18 billion of its value...

UPDATE 4-Biogen scraps two Alzheimer drug trials, wipes $18 bln from market value

* Analysts question Biogen growth prospects (Recasts first paragraph, adds details; updates shares)

UPDATE 3-Biogen scraps Alzheimer drug trials, wiping $17 billion off its market value

* Analysts question Biogen's growth prospects (Adds context, details, background)

Biogen, Eisai scrap Alzheimer drug trials

Biogen Inc and Eisai Co Ltd said on Thursday they will discontinue two late-stage trials testing an experimental treatment for Alzheimer's disease.

Japan's Fujifilm buys biologics unit from Biogen to boost healthcare business

Japan's Fujifilm Holdings Corp will buy a drugmaking business from U.S.-based Biogen Inc for about $890 million to try to bolster its healthcare business as growth at its legacy photocopy operations stagnates.

Fujifilm says to buy Biogen's subsidiary for around $890 mln

Fujifilm Holdings Corp said on Tuesday it is buying a subsidiary of Biogen Inc , Biogen Denmark Manufacturing ApS, for around $890 million to bolster its healthcare business.

Biogen to buy Nightstar Therapeutics in $800 mln cash deal

Biogen Inc said on Monday it will buy Nightstar Therapeutics Plc for about $800 million in cash as the company looks to tap into a potentially lucrative gene therapy market.

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up